Lantheus moves forward with study of 18F-flurpiridaz for MPI

05/1/2013 | AuntMinnie.com (free registration)

Lantheus Medical Imaging said the first Phase III trial involving its 18F-flurpiridaz PET agent has cleared a data analysis milestone, and the research will continue. The program comprises two trials involving 1,400 North American and European patients. The agent is being tested in myocardial perfusion imaging of patients believed or known to have coronary artery disease.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC